Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function Mutation
Tovorafenib demonstrated efficacy in BRAF fusion but not in NF1-LOF mutant tumor models. Vertical pathway inhibition by combining type II RAF plus MEK inhibitors may have clinical relevance in NF1-LOF mutant tumors.
Authors
- Yujin Wang (ORCID: https://orcid.org/0009-0008-0022-967X)
- Eleni Venetsanakos
- Madhu Lal-Nag
- Samantha Perino
- Samuel C. Blackman (ORCID: https://orcid.org/0000-0003-1076-8921)
- Shubhra Rastogi
Institutions
- National Institutes of Health (US)
- NGM Biopharmaceuticals (United States) (US)
- National Center for Advancing Translational Sciences (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-03-20
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0451
- Citations
- 3
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 2.42